Filenews 14 July 2022
A total of seven medicines for patients with type 2 diabetes mellitus are included in the GHS.
According to an announcement by the HIO, the following drugs are included in the category of SGLT-2 inhibitors:
- FORXIGA TABLET 10MG
- INVOKANA TABLET 100MG and INVOKANA TABLET 300MG
- JARDIANCE TABLET 10MG AND JARDIANCE TABLET 25MG
- STEGLATRO TABLET 15MG and STEGLATRO TABLET 5MG
- SYNJARDY TABLET 12.5MG/1000MG, SYNJARDY TABLET 12.5MG/850MG, SYNJARDY TABLET 5MG/1000MG and SYNJARDY TABLET 5MG/850MG
- VOKANAMET TABLET 150MG/1000MG,VOKANAMET TABLET 150MG/850MG, VOKANAMET TABLET 50MG/1000MG, VOKANAMET TABLET 50MG/850MG
- XIGDUO TABLET 5MG/1000MG, XIGDUO TABLET 5MG/850MG
The prescribing through the Information Technology System of the GHS of the above pharmaceutical products will be possible if:
- is done by Adult Personal Doctors, geriatricians and endocrinologists
- the beneficiaries fulfil the criteria of the Protocol.
Beneficiaries are kindly requested to contact their treating physician in order to be informed whether they meet these criteria.
Reimbursement of intravitreal administration and cost of the medicinal product Avastin
Also, the Health Insurance Organization informs the beneficiaries that both the intravitreal administration and the cost of the pharmaceutical product Avastin (Bevacizumab) are fully reimbursed by the GHS, provided that the criteria set by the Organization are met.
Specifically, this medicinal product is included in the medicinal products reimbursed by the Agency following a request for pre-authorisation, on the basis of the following indications:
- Age-related macular degeneration of the wet-type macula
- Macular edema after retinal vein occlusion .
- Diabetic macular edema
- Diabetic Retinopathy
Therefore, under no circumstances may beneficiaries be charged for the cost of the medicinal product or the intravitreal administration of the product in question, provided that the administration concerns one of the above indications covered by the Agency.
